JEJacob D. Estes

Jacob D. Estes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jacob D. Estes has a total of 602 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Spatial transcriptomics of pediatric tuberculosis lymph nodes reveals a conserved hypoxia–SPP1 niche

    by S. Odunola Adebiyi, Pierre Goussard, Daniël R. De Wet, Jacques T. Janson, Tracey Jooste, Ayanda Shabangu, Anca Dorhoi, Stephen Bondoc, Michael Nekorchuk, Michael C. Chao, et al.

    Pediatric tuberculosis (TB) often presents as primary disease involving the mediastinal lymph nodes; however, its granuloma microenvironment remains poorly characterized because these population patient tissues are rarely available for study. Here, we use spatial transcriptomics to profile 60 granulomas from four children aged 4 to 36 months. We identified nine recurrent transcriptional microenvironments shared across granulomas, despite their marked histological heterogeneity. One macrophage-rich microenvironment showed strong hypoxia-associated activity and secreted phosphoprotein 1 (SPP1) enrichment. This microenvironment was present in both non-necrotic and necrotic lesions and overlapped with a Mtb-persistence macrophage signature previously identified in murine TB lymph nodes. Pathway analysis revealed the enrichment of both antimicrobial and regulatory programs within this microenvironment, suggesting partial immune control rather than uniform inflammatory or suppressive activity in this region. SPP1 expression was associated with regions enriched for both M1- and M2-like macrophages, suggesting a macrophage program that extends beyond conventional polarization classifications and may be influenced by the local granuloma microenvironment. We further observed a similar spatial association between hypoxia-associated activity and SPP1 expression in an independent adult TB dataset (pooled Spearman ρ=0.65) and validated this association at protein level by multiplex immunofluorescence in our pediatric TB granuloma sample. Overall, this study identified a hypoxia-associated SPP1 -enriched microenvironment that may contribute to incomplete bacterial clearance and could provide a framework for evaluating host-directed strategies to enhance sterilizing immunity without exacerbating tissue damage.

  • Open Access

    SIV reservoir depletion and clearance from neonatal macaques following transient CCR5 depletion

    by Jesse D. Deere, David Merriam, Kawthar Machmach, W. L. William Chang, Michael Nekorchuk, Gema Méndez-Lagares, Hung Kieu, Joseph Dutra, Justin Fontaine, Denise R. Andal, et al.

    Antiretroviral therapy (ART) suppresses viraemia in people with human immunodeficiency virus (HIV), but HIV provirus persists indefinitely in CD4-expressing cells. Cells containing active provirus express viral proteins and have been successfully targeted using broadly neutralizing antibodies (bnAbs). In contrast, cells containing latent provirus cannot be specifically targeted without latency reactivation. Meaningful depletion of the latent HIV or simian immunodeficiency virus (SIV) reservoirs has not been demonstrated except with cytotoxic conditioning for bone-marrow transplantation. Here we show that both the active and latent SIV reservoirs can be eliminated from infant macaques via profound but transient depletion of cells that express CCR5 using a single shot of CCR5/CD3 bispecific antibody. Neonatal rhesus macaques were infected with SIVmac251, then treated with ART beginning at 1 week after infection, followed by treatment with either a CCR5/CD3-bispecific or a CD4-specific antibody, both of which depleted target cells and accelerated the decline in plasma viraemia. Upon ART cessation, while rebound occurred quickly in all animals treated with ART alone, most animals treated with CCR5/CD3 bispecific antibody remained aviraemic for >3 months. Several remained aviraemic to the end of follow-up and efforts to detect replication-competent virus were unsuccessful. Our results show that bispecific antibody treatment achieves meaningful depletion of the replication-competent SIV reservoir and supports the possibility that clinically meaningful depletion of the HIV reservoir might be achievable for recently infected individuals.


  • Open Access

    First-line dolutegravir/lamivudine in HIV-1 infection: lymph node penetration and reservoir decline in a randomized open-label clinical trial

    by Elias P. Rosen, Stephen Bondoc, Lucía Bailón, Lidia Blay, Albert Caballero, Maria C. García-Guerrero, Maria C. Puertas, Igor Moraes-Cardoso, Andrea Vazquez-Escobales, Julià Blanco, et al.

    Dual antiretroviral therapy with dolutegravir and lamivudine (DTG/3TC) is a recommended first-line regimen for people with HIV, but whether reduced-drug therapy maintains adequate antiviral pressure within lymph node (LN) reservoirs remains uncertain. In the DUALITY clinical trial (EudraCT number 2019-002733-10), the prespecified primary endpoint—change in proviral HIV-1 DNA in peripheral blood CD4 + T cells from baseline to week 48—was similar between participants initiating DTG/3TC or dolutegravir-based triple therapy. Here, we investigated prespecified secondary endpoints comprising viral persistence and antiretroviral drug penetration and distribution in LN using multimodal imaging. In 39 participants undergoing inguinal LN excision at baseline or during the first year of treatment, HIV-1 DNA and RNA were detected by DNAscope/RNAscope and antiretroviral spatial distribution was mapped by mass spectrometry imaging. HIV-1–infected cells declined rapidly after treatment initiation across both treatment groups. Antiretrovirals were widely detected within LN tissue regions containing or adjacent to HIV-positive cells. These findings provide spatial evidence that DTG/3TC reaches LN tissue and HIV-positive cells, extending peripheral blood observations to a key anatomical HIV reservoir.

  • New horizons in HIV neuropathogenesis: thinking beyond the brain

    by Thomas A. Angelovich, Kathleen Busman-Sahay, Janna Jamal Eddine, Melissa J. Churchill, Afam A. Okoye, Jacob D. Estes

    Purpose of review: Neurocognitive disorders and neuropathology continue to affect a subset of people with HIV (PWH) despite long-term viral suppression with antiretroviral therapy (ART). The mechanisms driving persistent neuropathology remain incompletely defined, and current therapeutic options are largely nonspecific and patient-dependent. This review analyses emerging evidence on HIV-associated neuropathology in ART-suppressed PWH, with a particular focus on the role of the gut–brain axis. Recent findings: Recent studies demonstrate that the CNS is a stable and transcriptionally active tissue reservoir, which may sustain chronic microglial activation, pro-inflammatory signalling, and synaptic injury. In parallel, accumulating evidence implicates systemic inflammation and gut barrier dysfunction as key contributors to neuroinflammation, linking microbial translocation and gut–brain axis perturbations to cognitive decline in PWH. Furthermore, persistent gut inflammation may result in enteric nervous system (ENS) dysfunction and aberrant signals that directly results in neuroinflammation and neuropathology. These mechanistic insights have driven evaluation of adjunctive strategies targeting HIV transcription and inflammatory pathways as potential approaches to limit neuropathogenesis. Summary: Neuropathology in ART-suppressed PWH arises from convergent processes involving CNS HIV reservoirs, myeloid-driven neuroinflammation, systemic immune activation and gut-derived injury, rather than residual brain infection alone. Defining the relative contribution of these pathways in PWH and developing CNS-penetrant interventions that silence viral transcription, restore gut integrity and dampen systemic inflammation, will be critical to preventing and treating HIV-associated neuropathology.

  • Open Access

    Distinct phases of immune system programming during ART-suppressed immunodeficiency virus infection

    by Maanasa Kaza, Benjamin Varco-Merth, GW McElfresh, Sebastian Benjamin, Gregory J. Boggy, Morgan Chaunzwa, Shana Feltham, Sohita Ojha, Karina Belica, Andrea N. Selseth, et al.

    People living with HIV (PLWH) on suppressive antiretroviral therapy (ART) can face non-AIDS complications, partially driven by chronic immune activation. To define immune perturbations during ART-suppressed viral infection, we performed longitudinal single-cell transcriptomic and plasma proteomic analysis of rhesus macaques infected with SIVmac239M and ART-treated for 70 weeks. We identified broad, bi-phasic immune changes. Acute infection involves an interferon-driven signature, correlated with viral replication, that largely resolves with viral control. Cell-associated virus correlated with interferon-stimulated genes in most tissues; however, this was blunted in gut-associated lymph nodes, a feature that may contribute to reservoir persistence. Separate alterations manifest 54-66 weeks-post-infection, after 40 weeks of viral suppression, including broad TGF-β and NF-kB signaling and discrete bursts of inflammatory monocytes, largely restricted to bone marrow. These data highlight the biphasic remodeling of long-term ART-suppressed HIV, identifying specific tissues and cell populations with dysregulation, with implications for the treatment of PLWH.

  • Open Access

    Rapid systemic spread and minimal immune responses following SIVsab intrarectal transmission in African green monkeys

    by Kevin D. Raehtz, Cuiling Xu, Claire Deleage, Dongzhu Ma, Benjamin B. Policicchio, Egidio Brocca-Cofano, Daniele Piccolo, Kathryn Weaver, Brandon F. Keele, Jacob D. Estes, et al.

    African green monkeys (AGMs) are natural hosts of SIV whose infection does not progress to AIDS. Since early events of infection may be critical to pathogenesis in nonnatural hosts, we investigated early SIV infection in 29 adult male AGMs intrarectally inoculated with SIVsab92018 (SIVsab) and serially sacrificed throughout acute into early chronic infection to understand patterns of viral establishment, dissemination, and their effect on disease progression. Using this model, we showed that foci of virus replication could be detected at the site of inoculation and in the draining lymphatics as early as 1–3 days postinfection (dpi). Furthermore, testing with ultrasensitive assays showed rapid onset of viremia (2–4 dpi). After systemic spread, virus was detected in all tissues surveyed. Multiple transmitted/founder viruses were identified, confirming an optimal challenge dose, while demonstrating a moderate mucosal genetic bottleneck. Resident CD4 + T cells were the initial target cells; other immune cell populations were not significantly altered at the site of entry. Thus, intrarectal SIVsab infection is characterized by swift dissemination of the virus, a lack of major target cell recruitment, and no window of opportunity for interventions to prevent virus dissemination during the earliest stages of infection, similar to intrarectal transmission but different from vaginal transmission in macaques.


  • Open Access

    Regional Analysis of Intact and Defective HIV Proviruses in the Brain of Viremic and Virally Suppressed People with HIV

    by Thomas A. Angelovich, Catherine R. Cochrane, Jingling Zhou, Carolin Tumpach, Sarah J. Byrnes, Janna Jamal Eddine, Emily Waring, Kathleen Busman‐Sahay, Claire Deleage, Trisha A. Jenkins, et al.

    Here, we provide the first regional analysis of intact and defective HIV reservoirs within the brain. Brain tissue from both viremic and virally suppressed people with HIV (PWH) harbored HIV pol DNA in all regions tested, with lower levels present in basal ganglia and cerebellum relative to frontal white matter. Intact proviruses were primarily found in the frontal white matter but also detected in other brain regions of PWH, demonstrating frontal white matter as a major brain reservoir of intact, potentially replication competent HIV DNA that persists despite antiretroviral therapy. ANN NEUROL 2023;94:798–802


  • Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques

    by Elise G. Viox, Timothy N. Hoang, Amit A. Upadhyay, Rayhane Nchioua, Maximilian Hirschenberger, Zachary Strongin, Gregory K. Tharp, Maria Pino, Kevin Nguyen, Justin L. Harper, et al.

    Type I interferons (IFN-I) are critical mediators of innate control of viral infections but also drive the recruitment of inflammatory cells to sites of infection, a key feature of severe coronavirus disease 2019. Here, IFN-I signaling was modulated in rhesus macaques (RMs) before and during acute SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection using a mutated IFN-α2 (IFN-modulator; IFNmod), which has previously been shown to reduce the binding and signaling of endogenous IFN-I. IFNmod treatment in uninfected RMs was observed to induce a modest up-regulation of only antiviral IFN-stimulated genes (ISGs); however, in SARS-CoV-2–infected RMs, IFNmod reduced both antiviral and inflammatory ISGs. IFNmod treatment resulted in a potent reduction in SARS-CoV-2 viral loads both in vitro in Calu-3 cells and in vivo in bronchoalveolar lavage (BAL), upper airways, lung, and hilar lymph nodes of RMs. Furthermore, in SARS-CoV-2–infected RMs, IFNmod treatment potently reduced inflammatory cytokines, chemokines, and CD163 + MRC1 − inflammatory macrophages in BAL and expression of Siglec-1 on circulating monocytes. In the lung, IFNmod also reduced pathogenesis and attenuated pathways of inflammasome activation and stress response during acute SARS-CoV-2 infection. Using an intervention targeting both IFN-α and IFN-β pathways, this study shows that, whereas early IFN-I restrains SARS-CoV-2 replication, uncontrolled IFN-I signaling critically contributes to SARS-CoV-2 inflammation and pathogenesis in the moderate disease model of RMs.


  • Open Access

    Non-Human Primate Models of HIV Brain Infection and Cognitive Disorders

    by Sarah J. Byrnes, Thomas A. Angelovich, Kathleen Busman-Sahay, Catherine R. Cochrane, Michael Roche, Jacob D. Estes, Melissa J. Churchill

    Human Immunodeficiency virus (HIV)-associated neurocognitive disorders are a major burden for people living with HIV whose viremia is stably suppressed with antiretroviral therapy. The pathogenesis of disease is likely multifaceted, with contributions from viral reservoirs including the brain, chronic and systemic inflammation, and traditional risk factors including drug use. Elucidating the effects of each element on disease pathogenesis is near impossible in human clinical or ex vivo studies, facilitating the need for robust and accurate non-human primate models. In this review, we describe the major non-human primate models of neuroHIV infection, their use to study the acute, chronic, and virally suppressed infection of the brain, and novel therapies targeting brain reservoirs and inflammation.


  • Open Access

    Intact HIV Proviruses Persist in the Brain Despite Viral Suppression with ART

    by Catherine R. Cochrane, Thomas A. Angelovich, Sarah J. Byrnes, Emily Waring, Aleks C. Guanizo, Gemma S. Trollope, Jingling Zhou, Judith Vue, Lachlan Senior, Emma Wanicek, et al.

    Objective: Human immunodeficiency virus (HIV) persistence in blood and tissue reservoirs, including the brain, is a major barrier to HIV cure and possible cause of comorbid disease. However, the size and replication competent nature of the central nervous system (CNS) reservoir is unclear. Here, we used the intact proviral DNA assay (IPDA) to provide the first quantitative assessment of the intact and defective HIV reservoir in the brain of people with HIV (PWH).Methods: Total, intact, and defective HIV proviruses were measured in autopsy frontal lobe tissue from viremic (n = 18) or virologically suppressed (n = 12) PWH. Total or intact/defective proviruses were measured by detection of HIV pol or the IPDA, respectively, through use of droplet digital polymerase chain reaction (ddPCR). HIV‐seronegative individuals were included as controls (n = 6).Results: Total HIV DNA was present at similar levels in brain tissues from untreated viremic and antiretroviral (ART)‐suppressed individuals (median = 22.3 vs 26.2 HIV pol copies/106 cells), reflecting a stable CNS reservoir of HIV that persists despite therapy. Furthermore, 8 of 10 viremic and 6 of 9 virally suppressed PWH also harbored intact proviruses in the CNS (4.63 vs 12.7 intact copies/106 cells). Viral reservoirs in CNS and matched lymphoid tissue were similar in the composition of intact and/or defective proviruses, albeit at lower levels in the brain. Importantly, CNS resident CD68+ myeloid cells in virally suppressed individuals harbored HIV DNA, directly showing the presence of a CNS resident HIV reservoir.Interpretation: Our results demonstrate the first evidence for an intact, potentially replication competent HIV reservoir in the CNS of virally suppressed PWH. ANN NEUROL 2022;92:532–544